These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Is amisulpride an 'atypical' atypical antipsychotic agent? Author: Lecrubier Y. Journal: Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520. Abstract: Amisulpride is a novel antipsychotic with a pharmacological and clinical profile that differs from that of other atypical agents. Amisulpride is highly selective for dopamine D2/D3 receptor subtypes located in the limbic region, which is highly predictive of potent antipsychotic activity with a low potential to cause extrapyramidal symptoms (EPS). At the same time, its selective activity at presynaptic D2/D3 receptors is responsible for enhancing dopamine transmission, which predicts efficacy in the treatment of the negative symptoms of schizophrenia. Amisulpride thus has a unique profile: efficacy in controlling the symptoms of schizophrenia, whether predominantly positive or negative, combined with a low incidence of EPS. This profile is seen during both acute and chronic treatment. Amisulpride is therefore indeed an 'atypical atypical'--a flexible antipsychotic the use of which can be tailored to the changing needs of the patient. It is thus a suitable first-line choice for the treatment of schizophrenia.[Abstract] [Full Text] [Related] [New Search]